John R Mascola
Overview
Explore the profile of John R Mascola including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
543
Citations
46691
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Happe M, Lynch R, Fichtenbaum C, Heath S, Koletar S, Landovitz R, et al.
JCI Insight
. 2025 Feb;
10(4).
PMID: 39989458
BACKGROUNDHIV-1-specific broadly neutralizing monoclonal antibodies (bNAbs) have emerged as promising interventions with the potential to effectively treat and prevent HIV-1 infections. We conducted a phase I clinical trial evaluating the...
2.
Joyce M, Bu W, Chen W, Gillespie R, Andrews S, Wheatley A, et al.
Immunity
. 2025 Feb;
58(2):295-308.e5.
PMID: 39909035
Epstein-Barr virus (EBV) causes infectious mononucleosis and is associated with malignancies in humans. Viral infection of B cells is initiated by the viral glycoprotein 350 (gp350) binding to complement receptor...
3.
Abiona O, Wang N, Leist S, Schafer A, Cockrell A, Wang L, et al.
iScience
. 2025 Feb;
28(2):111632.
PMID: 39898019
The COVID-19 pandemic underscores the need to prepare for future emerging coronavriuses (CoVs) by understanding the principles behind effective CoV vaccine design such as protective immunity and antibody responses. To...
4.
Kanekiyo M, Gillespie R, Cooper K, Canedo V, Castanha P, Pegu A, et al.
Science
. 2025 Jan;
387(6733):534-541.
PMID: 39883776
Influenza virus pandemics and seasonal epidemics have claimed countless lives. Recurrent zoonotic spillovers of influenza viruses with pandemic potential underscore the need for effective countermeasures. In this study, we show...
5.
Cale E, Shen C, Olia A, Radakovich N, Rawi R, Yang Y, et al.
Cell Rep
. 2024 Dec;
43(12):115010.
PMID: 39675002
Antibodies that target the gp120-gp41 interface of the HIV-1 envelope (Env) trimer comprise a commonly elicited category of broadly neutralizing antibodies (bNAbs). Here, we isolate and characterize VRC44, a bNAb...
6.
Lemos M, Astronomo R, Huang Y, Narpala S, Prabhakaran M, Mann P, et al.
Nat Commun
. 2024 Nov;
15(1):10332.
PMID: 39609400
To prevent sexually-acquired HIV-1 infection by immunoprophylaxis, effective concentrations of broadly neutralizing antibodies are likely needed at mucosal sites of exposure. Here, we examine the biodistribution of monoclonal antibody VRC01...
7.
Loomis R, Lai Y, Sowers S, Fisher B, Derrien-Colemyn A, Ambrozak D, et al.
Proc Natl Acad Sci U S A
. 2024 Nov;
121(47):e2404053121.
PMID: 39527740
Mumps virus (MuV) is a highly contagious paramyxovirus that is endemic in most regions of the world and continues to cause outbreaks even in highly immunized populations. Outbreaks of mumps...
8.
Wang H, Cheng C, Dal Santo J, Shen C, Bylund T, Henry A, et al.
Cell
. 2024 Oct;
187(25):7214-7231.e23.
PMID: 39471811
An antibody-based HIV-1 vaccine will require the induction of potent cross-reactive HIV-1-neutralizing responses. To demonstrate feasibility toward this goal, we combined vaccination targeting the fusion-peptide site of vulnerability with infection...
9.
Misasi J, Wei R, Wang L, Pegu A, Wei C, Oloniniyi O, et al.
Sci Transl Med
. 2024 Oct;
16(768):eado9026.
PMID: 39383243
Despite effective countermeasures, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) persists worldwide because of its ability to diversify and evade human immunity. This evasion stems from amino acid substitutions, particularly...
10.
Casazza J, Hofstetter A, Costner P, Holman L, Hendel C, Widge A, et al.
NPJ Vaccines
. 2024 Sep;
9(1):171.
PMID: 39289377
The relative conservation of the influenza hemagglutinin (HA) stem compared to that of the immunodominant HA head makes the HA stem an attractive target for broadly protective influenza vaccines. Here...